EXEL

In the past six months, Exelixis's stock has been impacted by several key events, including surpassing analyst expectations with its quarterly earnings reports. In the first quarter of 2026, Exelixis reported non-GAAP diluted EPS of $0.87 and total revenues of $610.8 million, leading to a positive market reaction. The company authorized an additional $750 million stock repurchase plan in May 2026. The FDA accepted the NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer in February 2026, with a PDUFA target action date of December 3, 2026. Over the past 52 weeks, Exelixis stock has traded between $33.76 and $49.62.